AU2019409912B2 - 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders - Google Patents

3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders Download PDF

Info

Publication number
AU2019409912B2
AU2019409912B2 AU2019409912A AU2019409912A AU2019409912B2 AU 2019409912 B2 AU2019409912 B2 AU 2019409912B2 AU 2019409912 A AU2019409912 A AU 2019409912A AU 2019409912 A AU2019409912 A AU 2019409912A AU 2019409912 B2 AU2019409912 B2 AU 2019409912B2
Authority
AU
Australia
Prior art keywords
3bn17mep
cognitive
route
rimonabant
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019409912A
Other languages
English (en)
Other versions
AU2019409912A1 (en
AU2019409912A8 (en
Inventor
Daniela COTA
Sandy FABRE
Rafael MALDONADO
Aline MARIGHETTO
Giovanni Marsicano
Mathilde METNA
Stéphanie MONLEZUN
Andrés OZAITA
Pier-Vincenzo Piazza
Jean-Michel REVEST
Monique VALLEE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Université de Bordeaux
Aelis Farma SA
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Université de Bordeaux
Aelis Farma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Université de Bordeaux, Aelis Farma SA filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of AU2019409912A1 publication Critical patent/AU2019409912A1/en
Publication of AU2019409912A8 publication Critical patent/AU2019409912A8/en
Application granted granted Critical
Publication of AU2019409912B2 publication Critical patent/AU2019409912B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2019409912A 2018-12-18 2019-12-18 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders Active AU2019409912B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306716.4 2018-12-18
EP18306716.4A EP3669876A1 (en) 2018-12-18 2018-12-18 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
PCT/EP2019/085927 WO2020127468A1 (en) 2018-12-18 2019-12-18 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS

Publications (3)

Publication Number Publication Date
AU2019409912A1 AU2019409912A1 (en) 2021-05-27
AU2019409912A8 AU2019409912A8 (en) 2021-06-17
AU2019409912B2 true AU2019409912B2 (en) 2025-02-20

Family

ID=65278139

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019409912A Active AU2019409912B2 (en) 2018-12-18 2019-12-18 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders

Country Status (26)

Country Link
US (1) US12583884B2 (cg-RX-API-DMAC7.html)
EP (2) EP3669876A1 (cg-RX-API-DMAC7.html)
JP (1) JP7515480B2 (cg-RX-API-DMAC7.html)
KR (1) KR102845328B1 (cg-RX-API-DMAC7.html)
CN (1) CN113260366B (cg-RX-API-DMAC7.html)
AU (1) AU2019409912B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011654A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118210C (cg-RX-API-DMAC7.html)
CL (1) CL2021001458A1 (cg-RX-API-DMAC7.html)
DK (1) DK3897655T3 (cg-RX-API-DMAC7.html)
ES (1) ES2987823T3 (cg-RX-API-DMAC7.html)
FI (1) FI3897655T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241376T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068626T2 (cg-RX-API-DMAC7.html)
IL (1) IL284032B2 (cg-RX-API-DMAC7.html)
LT (1) LT3897655T (cg-RX-API-DMAC7.html)
MA (1) MA54518B1 (cg-RX-API-DMAC7.html)
MD (1) MD3897655T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006904A (cg-RX-API-DMAC7.html)
PL (1) PL3897655T3 (cg-RX-API-DMAC7.html)
PT (1) PT3897655T (cg-RX-API-DMAC7.html)
RS (1) RS66013B1 (cg-RX-API-DMAC7.html)
SI (1) SI3897655T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400425T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020127468A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103284B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007382A (es) 2018-12-18 2021-07-15 Merck Sharp & Dohme Llc Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih.
WO2024085245A1 (ja) 2022-10-21 2024-04-25 国立大学法人高知大学 術後せん妄の抑制薬

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160145294A1 (en) * 2011-05-20 2016-05-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonists of CB1 Receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004234125A1 (en) 2003-05-01 2004-11-11 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders
ATE496894T1 (de) 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
CN101790521A (zh) 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
RU2667065C2 (ru) * 2012-11-28 2018-09-14 Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) Производные прегненолона
LT2976074T (lt) * 2013-03-19 2020-03-25 Universitat Pompeu-Fabra Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis
IL276697B2 (en) 2018-02-20 2024-08-01 Aelis Farma 3beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160145294A1 (en) * 2011-05-20 2016-05-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonists of CB1 Receptor

Also Published As

Publication number Publication date
HUE068626T2 (hu) 2025-01-28
DK3897655T3 (da) 2024-09-23
IL284032A (en) 2021-08-31
CN113260366B (zh) 2024-03-08
HRP20241376T1 (hr) 2024-12-20
MA54518B1 (fr) 2024-11-29
AU2019409912A1 (en) 2021-05-27
JP7515480B2 (ja) 2024-07-12
PL3897655T3 (pl) 2025-01-13
KR102845328B1 (ko) 2025-08-12
IL284032B1 (en) 2025-01-01
EP3897655B1 (en) 2024-07-17
MD3897655T2 (ro) 2024-12-31
PT3897655T (pt) 2024-10-14
AU2019409912A8 (en) 2021-06-17
KR20210124962A (ko) 2021-10-15
US20220017562A1 (en) 2022-01-20
SI3897655T1 (sl) 2025-04-30
RS66013B1 (sr) 2024-10-31
BR112021011654A2 (pt) 2021-09-08
WO2020127468A1 (en) 2020-06-25
CL2021001458A1 (es) 2022-01-21
EP3897655A1 (en) 2021-10-27
CA3118210A1 (en) 2020-06-25
MA54518A (fr) 2022-02-16
US12583884B2 (en) 2026-03-24
CA3118210C (en) 2024-05-21
SMT202400425T1 (it) 2024-11-15
CN113260366A (zh) 2021-08-13
JP2022515373A (ja) 2022-02-18
ES2987823T3 (es) 2024-11-18
FI3897655T3 (fi) 2024-09-17
ZA202103284B (en) 2024-09-25
LT3897655T (lt) 2024-10-10
MX2021006904A (es) 2021-09-30
EP3669876A1 (en) 2020-06-24
IL284032B2 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
US20230218617A1 (en) Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
JP2009102343A (ja) ダウン症候群を有する成人において認知低下を阻害する方法
NO327233B1 (no) Anvendelse av en glukokortikoidreseptorantagonist for fremstilling av et medikament til forbedring av psykose hos en pasient.
US20130123248A1 (en) Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression
US12583884B2 (en) 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
JP2003527342A (ja) 軽度認知障害を処置する方法
US20230226076A1 (en) 3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of Cannabinoids-Related Disorders
RU2796005C2 (ru) 3β-(БЕНЗИЛОКСИ)-17α-МЕТИЛ-ПРЕГН-5-ЕН-20-ОН ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ КОГНИТИВНЫХ РАССТРОЙСТВ
HK40060558B (en) 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
HK40060558A (en) 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
US7163934B2 (en) Methods for treating delirium glucocorticoid receptor-specific antagonists
Class et al. Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research
AU2002335678A1 (en) Methods for inhibiting cognitive deterioration in adults with down's syndrome

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 35 , NO 21 , PAGE(S) 4518 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAMES FARMA, AELIS; UNIVERSITE DE BORDEAUX; INSTITUT-NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, APPLICATION NO. 2019409912, UNDER INID (71) CORRECT THE APPLICANT NAME TO INSERM-INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FGA Letters patent sealed or granted (standard patent)